NCT07648225
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 25 words
- Trial status changed: Not Yet Recruiting → Active, Not Recruiting
- Start date changed from estimate of Jul 31, 2026 to Sep 4, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Each subject will receive UBT251 Injection s.c. once weekly for 52 weeks. Each dose group will be titrated starting from the initial dose, administered once weekly, and escalated to the next dose after 4 weeks until the target maintenance dose is reached, with a total treatment duration of 52 weeks.
Each subject will receive UBT251 Injection, s.c. once weekly for 52 weeks. Each dose group will be titrated starting from the initial dose, administered once weekly, and escalated to the next dose after 4 weeks until the target maintenance dose is reached, with a total treatment duration of 52 weeks.
Each subject will receive UBT251 Injection Placebo, s.c. once weekly for 52 weeks. Each dose group will be titrated starting from the initial dose, administered once weekly, and escalated to the next dose after 4 weeks until the target maintenance dose is reached, with a total treatment duration of 52 weeks.
Each subject will receive UBT251 Injection Placebo, s.c. once weekly for 52 weeks. Each dose group will be titrated starting from the initial dose, administered once weekly, and escalated to the next dose after 4 weeks until the target maintenance dose is reached, with a total treatment duration of 52 weeks.
Drugs: UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mg, UBT251 Injection Placebo 4.0 mg, UBT251 Injection Placebo 6.0 mg
Sites
1 site in 1 country
- Peking University People's HospitalBeijing, China